Booking Gains on Keryx and What to Look for Next
Research - Why we're booking gains on Keryx (KERX) and an options strategy for the Sept. 7 PDUFA decision on Zerenex.
Read nowMust Read
Obesity & PD-1: History Doesn’t Repeat But It Rhymes
The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical Submits 510(k) for Insulin Patch Pump
Modular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumLatest Posts
Infinity Pharma’s Cancer Drug Just Became Cool Again
Insights - Infinity Pharmaceuticals (INFI) and AbbVie Inc. (ABBV) have entered into a major partnership to develop and commercialize duvelisib (IPI-145), Infinity’s oral phosphoinositide-3-kinase (PI3K) inhibitor. PI3K inhibitors were the cat’s meow in … Continue Reading
Read now
There’s a Lesson to be Learned from Ampio’s Failed STEP Study
Insights - Ampio Pharmaceuticals (AMPE) reported results from the botched STEP Study on Tuesday morning, spinning the failed trial of Ampion in osteoarthritis of the knee as positively … Continue Reading
Read now
Biotechnology Stocks are Making New All-Time Highs
Recap - Six weeks after Federal Reserve Chairwoman Janet Yellen called biotechnology valuations “substantially stretched” the NASDAQ Biotechnology Index (IBB) is setting new records right alongside the S&P 500. It’s … Continue Reading
Read nowA Strategy for Alcobra’s Do or Die Phase 3 Results
Research - A risk-mitigating strategy for being involved in Alcobra’s (ADHD) upcoming phase 3 results in ADHD.
Premium
Investors Had One Helluva Week
Insights - It was a reckless day, with securities across the board halted by circuit-breakers, and some discount brokers having difficulty even placing orders.
Read now
GlaxoSmithKline Isn’t Buying Tekmira for its Ebola Drug
Insights - Ebola stocks are still in vogue, though for new reasons on Thursday. The DailyMail reported on Wednesday evening that up to four drug companies, including Shire … Continue Reading
Read now